Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
5 drugs in development
By Therapeutic Area
top 1
R&D Momentum
71/100
Pipeline Velocity
42/100
Trial Completion Rate
83/100
Pipeline Concentration
100/100
Pipeline Freshness
75/100
Strategic Signals
Activity
Last 14 days
Pirfenidone Versus Placebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following Hypofractionated Radiotherapy in Breast Cancer Patients (PRILI): A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating
Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy: A Phase III Randomized, Controlled Clinical Trial
Adebrelimab With or Without Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Prospective, Phase 2 Trial
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma: an Exploratory Phase II Single-arm Clinical Study
Multicenter Prospective Randomized Controlled Study of Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone in the Treatment of pN1-2 (pT1b-3N1-2M0) Thoracic Esophageal Squamous Cell Carcinoma
Fuzhou Aging Brain Health Initiative--Health Aging and Alzheimer's Disease Cohort and Early Diagnosis and Treatment Research
Mechanisms and Intervention Strategies of Perioperative Glycemic Variability on Postoperative Delirium After Cardiac Surgery
Effects of Remote Ischemic Preconditioning at Different Time Phases on Clinical Outcomes in Patients Undergoing Heart Valve Surgery
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)